科学技术-科研成果

科学论文

Oral: Jia Fan, Zhenggang Ren, et al. Phase 2 study of HLX10 (a novel anti-PD-1 antibody) plus HLX04 (an anti-VEGF antibody) in patients with advanced hepatocellular carcinoma

CSCO 2021
Oral: Jin Li, Shukui Qin, et al. Phase 2 study of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumours

CSCO 2021
Oral: Jin Li, et al. HLX04 (a bevacizumab biosimilar candidate) versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line therapy for metastatic colorectal cancer: a randomised, double-blind phase 3 study

CSCO 2021
Shukui Qin, Jin Li, et al. Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study. Journal of Clinical Oncology 2021 39:15_suppl, 2566-2566. DOI: 10.1200/JCO.2021.39.15_suppl.2566

ASCO 2021
Lingying Wu, et al. Efficacy and safety evaluation of HLX10 (a recombinant humanized anti-PD-1 monoclonal antibody) combined with albumin-bound paclitaxel in patients with advanced cervical cancer who have progressive disease or intolerable toxicity after first-line standard chemotherapy: A single-arm, open-label, phase 2 study. Journal of Clinical Oncology 2021 39:15_suppl, e17510-e17510. DOI: 10.1200/JCO.2021.39.15_suppl.e17510

ASCO 2021
Zeng X, et al. AB0197 EFFICACY AND SAFETY OF HLX01 COMBINED WITH METHOTREXATE IN CHINESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD INADEQUATE RESPONSES TO METHOTREXATE: RESULTS OF A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY. Annals of the Rheumatic Diseases 2021;80:1122-1123. DOI:10.1136/annrheumdis-2021-eular.282

EULAR 2021

知识产权

相关产品	专利名称	专利持有人	专利编号	注册司法权区	申请日期	到期日	类别
平台技术	用于CHO细胞DNA残留检测的试剂盒及其使用方法	DB视讯	ZL201110066745.4	中国大陆	2011-03-18	2031-03-18	发明专利
平台技术	探针法检测CHO细胞DNA含量的方法	DB视讯	ZL201110099204.1	中国大陆	2011-04-20	2031-04-20	发明专利
技术平台	一种利用CHO细胞生产重组蛋白的真核表达载体及系统	DB视讯	ZL201210211812.1	中国大陆	2012/6/25	2032/6/25	发明专利
HLX07	抗表皮生长因子受体(EGFR)抗体	DB视讯	ZL201580029644.6 HK1252789 J/4492 TWI689520 US10584171 AU2015266664 JP6691872 EP3148581 EP3613433 KR102366644 US11261255	中国大陆中国香港中国澳门中国台湾美国澳大利亚日本欧洲（英法德意西）欧洲（英法德意西）韩国美国	2015-05-29	2035-05-29 2035-12-11	发明专利
汉斯状®（HLX10）	一种细胞程序性死亡受体1抗体制剂及其用途 ANTI-PD-1 ANTIBODIES; 抗PD-1抗体	DB视讯 DB视讯	ZL202010008058.6 HK40018285 ZA201901865 US11028173 RU2752832 JP7072576 ZL201780056868.5 TWI772326 KR102391338 IDP000083833	中国大陆中国香港南非美国俄罗斯日本中国大陆中国台湾韩国印度尼西亚	2020-01-06 2017/09/09	2040-01-06 2037/09/08 2037/09/09 2037/09/09 2037/09/15 2037/09/09 2037/09/09	发明专利
HLX53	抗TIGIT抗体和使用方法	DB视讯	ZL202010024565.9 HK40013828	中国大陆中国香港	2020-01-10	2040-1-10	发明专利
平台技术	在线监控目标蛋白的产量和质量的系统	DB视讯	ZL202020160862.1	中国大陆	2020-02-11	2030-02-10	实用新型专利
平台技术	在线目标蛋白定量检测系统	DB视讯	ZL202020432845.9	中国大陆	2020-03-30	2030-03-29	实用新型专利

DB视讯